Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on 4D Molecular Therapeutics (FDMT – Research Report), Revance Therapeutics (RVNC – Research Report) and CureVac (CVAC – Research Report).
4D Molecular Therapeutics (FDMT)
RBC Capital analyst Lisa Walter maintained a Buy rating on 4D Molecular Therapeutics yesterday and set a price target of $40.00. The company’s shares closed last Thursday at $25.64.
Walter has an average return of
According to TipRanks.com, Walter is ranked #1982 out of 8834 analysts.
4D Molecular Therapeutics has an analyst consensus of Strong Buy, with a price target consensus of $51.14, a 93.6% upside from current levels. In a report released today, Barclays also maintained a Buy rating on the stock with a $45.00 price target.
See the top stocks recommended by analysts >>
Revance Therapeutics (RVNC)
H.C. Wainwright analyst Douglas Tsao reiterated a Buy rating on Revance Therapeutics today and set a price target of $11.00. The company’s shares closed last Thursday at $4.29, close to its 52-week low of $3.21.
According to TipRanks.com, Tsao is a 4-star analyst with an average return of
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Revance Therapeutics with a $16.44 average price target, implying a 281.4% upside from current levels. In a report issued on May 8, Barclays also assigned a Buy rating to the stock with a $10.00 price target.
CureVac (CVAC)
In a report issued on May 8, Emmanuel Papadakis from Deutsche Numis maintained a Hold rating on CureVac, with a price target of $6.50. The company’s shares closed last Thursday at $2.98, close to its 52-week low of $2.22.
According to TipRanks.com, Papadakis is a 4-star analyst with an average return of
CureVac has an analyst consensus of Moderate Buy, with a price target consensus of $10.63, a 267.8% upside from current levels. In a report issued on April 25, Leerink Partners also reiterated a Hold rating on the stock with a $4.00 price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on FDMT:
- 4D Molecular price target raised to $40 from $35 at RBC Capital
- 4D Molecular initiated with an Overweight at Barclays
- 4D Molecular assumed with a Buy at Jefferies
- 4D Molecular price target lowered to $63 from $70 at BMO Capital
- 4D Molecular announce update on regulatory interactions, development for 4D-710
